Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | Senior VP, R&D | March 05, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date March 05, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,062 |
Reported balance
After 2026-03-05 transaction · row 1
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 5,284 · Balance 20,062 F1: Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $141.91 · Expires 2036-03-05 | Direct | 5,669 |
Reported balance
After 2026-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-05 · Grant · Acquired 5,669 · Balance 5,669 F2: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 23, 2022 00:34 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 450 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-007257 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,359 F1 · shares: Represents shares issued pursuant to a Performance Stock Unit ("PSU") award granted to the Issuer on January 4, 2021. The Compensation Committee authorized the issuance of the underlying shares based upon the Issuer's achievement of pre-established performance criteria set forth in the PSU award. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 02:30 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 445 | $252.53 | $112,375.85 |
DisclosureSEC source: 0000899243-21-048462 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,909 F1 · shares: Represents the number of shares that were withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the vesting of restricted stock units. Read SEC document |
| August 30, 2021 Filed Sep 2, 2021 10:54 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,001 | $282.13 | $1,128,802.13 |
DisclosureSEC source: 0000899243-21-034834 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,354 F1 · price: $282.13 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.10 to $282.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:48 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,045 | $0.00 Strike: $86.10 | $0.00 |
DisclosureSEC source: 0000899243-21-023674 · doc4.xml · derivative · entry 5 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,092 Underlying: Common Stock · 1,045 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1,045 of the shares underlying the option have vested. The remaining shares vest as follows: 1,046 shares on February 27, 2022 and February 27, 2023. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:48 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,557 | $0.00 Strike: $59.52 | $0.00 |
DisclosureSEC source: 0000899243-21-023674 · doc4.xml · derivative · entry 4 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354 Underlying: Common Stock · 2,557 shares Expires 2029-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 2,707 of the shares underlying the option have vested. The remaining 1,354 shares shall vest on February 28, 2022. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:48 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,802 | $189.19 | $1,286,870.38 |
DisclosureSEC source: 0000899243-21-023674 · doc4.xml · nonDerivative · entry 3 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,355 F1 · price: $189.19 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.70 to $189.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:48 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 1,045 | $86.10 | $89,974.50 |
DisclosureSEC source: 0000899243-21-023674 · doc4.xml · nonDerivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:48 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 2,557 | $59.52 | $152,192.64 |
DisclosureSEC source: 0000899243-21-023674 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2021 Filed May 18, 2021 11:50 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 710 | $172.29 | $122,325.90 |
DisclosureSEC source: 0000899243-21-019721 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,555 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F2 · price: $172.29 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.26 to $172.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 150 | $0.00 Strike: $59.52 | $0.00 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · derivative · entry 9 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,911 Underlying: Common Stock · 150 shares Expires 2029-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 2,707 of the shares underlying this option have vested. The remaining 1,354 shares shall vest on February 28, 2022. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,850 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · derivative · entry 8 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,850 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $33.05 | $0.00 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · derivative · entry 7 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 8,000 of the shares underlying this option have vested. The remaining 2,000 shares shall vest on December 14, 2021. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,004 | $192.13 | $192,898.52 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · nonDerivative · entry 6 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,265 F3 · price: $192.13 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.86 to $192.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 642 | $191.33 | $122,833.86 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · nonDerivative · entry 5 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,269 F2 · price: $191.33 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.79 to $191.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,354 | $190.08 | $1,207,768.32 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · nonDerivative · entry 4 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,911 F1 · price: $190.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.79 to $190.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 150 | $59.52 | $8,928.00 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · nonDerivative · entry 3 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 5,850 | $33.87 | $198,139.50 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · nonDerivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 2,000 | $33.05 | $66,100.00 |
DisclosureSEC source: 0000899243-21-011407 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:41 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 700 | $190.06 | $133,042.00 |
DisclosureSEC source: 0000899243-21-010542 · doc4.xml · nonDerivative · entry 5 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,265 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F6 · price: $190.06 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.47 to $190.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:41 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 600 | $191.20 | $114,720.00 |
DisclosureSEC source: 0000899243-21-010542 · doc4.xml · nonDerivative · entry 4 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,965 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F5 · price: $191.20 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.84 to $191.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:41 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 350 | $192.24 | $67,284.00 |
DisclosureSEC source: 0000899243-21-010542 · doc4.xml · nonDerivative · entry 3 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,565 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F4 · price: $192.24 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.20 to $192.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:41 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 25 | $194.30 | $4,857.50 |
DisclosureSEC source: 0000899243-21-010542 · doc4.xml · nonDerivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,915 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F3 · price: $194.30 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.17 to $194.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 02:41 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 400 | $196.23 | $78,492.00 |
DisclosureSEC source: 0000899243-21-010542 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,940 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F2 · price: $196.23 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.00 to $196.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:08 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,035 | $0.00 Strike: $215.58 | $0.00 |
DisclosureSEC source: 0000899243-21-008461 · doc4.xml · derivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,035 Underlying: Common Stock · 2,035 shares Expires 2031-02-24 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 24, 2022, February 24, 2023 and February 24, 2024. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:08 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 1,686 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008461 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,340 F1 · shares: Mr. Kuriyel was awarded 1,686 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 435 | $186.18 | $80,988.30 |
DisclosureSEC source: 0000899243-20-034483 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,654 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 21:35 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000899243-20-021896 · doc4.xml · derivative · entry 3 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,850 Underlying: Common Stock · 5,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 6,566 of the shares underlying this option have vested. 4,284 shares shall vest and become exercisable on March 1, 2021. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 21:35 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 5,000 | $153.79 | $768,950.00 |
DisclosureSEC source: 0000899243-20-021896 · doc4.xml · nonDerivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,089 F1 · price: $153.79 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.53 to $154.05, inclusive. The reporting person undertakes to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 21:35 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 5,000 | $33.87 | $169,350.00 |
DisclosureSEC source: 0000899243-20-021896 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:54 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 435 | $140.69 | $61,200.15 |
DisclosureSEC source: 0000899243-20-013642 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,089 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:37 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000899243-20-013273 · doc4.xml · derivative · entry 7 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,850 Underlying: Common Stock · 2,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 8,566 of the shares underlying this option have vested. The remaining 4,284 shares shall vest on March 1, 2021. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:37 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $33.05 | $0.00 |
DisclosureSEC source: 0000899243-20-013273 · doc4.xml · derivative · entry 6 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 6,000 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 6,000 of the shares underlying this option have vested. The remaining 4,000 shares shall vest in two equal installments on December 14, 2020 and December 14, 2021. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:37 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 95 | $128.55 | $12,212.25 |
DisclosureSEC source: 0000899243-20-013273 · doc4.xml · nonDerivative · entry 5 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,524 F3 · price: $128.55 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.54 to $128.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:37 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,293 | $128.02 | $805,629.86 |
DisclosureSEC source: 0000899243-20-013273 · doc4.xml · nonDerivative · entry 4 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,619 F2 · price: $128.02 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.53 to $128.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:37 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,612 | $126.88 | $204,530.56 |
DisclosureSEC source: 0000899243-20-013273 · doc4.xml · nonDerivative · entry 3 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,912 F1 · price: $126.88 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.36 to $127.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:37 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 2,000 | $33.87 | $67,740.00 |
DisclosureSEC source: 0000899243-20-013273 · doc4.xml · nonDerivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2020 Filed May 15, 2020 21:37 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 6,000 | $33.05 | $198,300.00 |
DisclosureSEC source: 0000899243-20-013273 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 22:53 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,905 | $90.99 | $173,335.95 |
DisclosureSEC source: 0000899243-20-007241 · doc4.xml · nonDerivative · entry 3 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,524 F3 · price: $90.99 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.83 to $91.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 22:53 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 650 | $90.08 | $58,552.00 |
DisclosureSEC source: 0000899243-20-007241 · doc4.xml · nonDerivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,429 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 22:53 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 450 | $88.35 | $39,757.50 |
DisclosureSEC source: 0000899243-20-007241 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,079 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. F2 · price: $88.35 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.31 to $88.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 00:37 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 3,137 | $0.00 Strike: $86.10 | $0.00 |
DisclosureSEC source: 0000899243-20-006613 · doc4.xml · derivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,137 Underlying: Common Stock · 3,137 shares Expires 2030-02-27 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 27, 2021, February 27, 2022 and February 27, 2023. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 00:37 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 3,216 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006613 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,529 F1 · shares: Mr. Kuriyel was awarded 3,216 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 22:38 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 195 | $86.60 | $16,887.00 |
DisclosureSEC source: 0000899243-20-006062 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,313 F1 · kind: Sale of shares in the open market to cover tax liability resulting from the release of restricted stock units. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:16 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 295 | $90.43 | $26,676.85 |
DisclosureSEC source: 0000899243-19-029536 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,508 F1 · shares: Represents the number of shares that were withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the vesting of restricted stock units. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:53 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013572 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,803 F1 · shares: Mr. Kuriyel was awarded 8,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a five-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 05, 2019 Filed Mar 5, 2019 22:34 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,240 | $58.53 | $131,107.20 |
DisclosureSEC source: 0000899243-19-006156 · doc4.xml · nonDerivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,803 F2 · kind: Sale of 2,240 shares in the open market to cover tax liability resulting from the release of restricted stock units and PSUs. F3 · price: $58.53 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.30 to $58.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:34 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006156 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,043 F1 · shares: Represents shares awarded pursuant to Performance Share Units ("PSUs"). The Compensation Committee authorized the issuance of the underlying shares based upon the Issuer's achievement of pre-established performance criteria related to the filing of the 2018 Annual Report on Form 10-K, which was filed on March 1, 2019. These PSUs vested on March 1, 2019. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:52 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 4,042 | $0.00 Strike: $59.52 | $0.00 |
DisclosureSEC source: 0000899243-19-005883 · doc4.xml · derivative · entry 3 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,042 Underlying: Common Stock · 4,042 shares Expires 2029-02-28 F3 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 28, 2020, February 28, 2021 and February 28, 2022. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:52 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 185 | $59.16 | $10,944.60 |
DisclosureSEC source: 0000899243-19-005883 · doc4.xml · nonDerivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,343 F2 · kind: Sale of 185 shares in the open market to cover tax liability resulting from the release of restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:52 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 4,234 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005883 · doc4.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,528 F1 · shares: Mr. Kuriyel was awarded 4,234 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.